News | EP Mapping and Imaging Systems | July 07, 2016

Abbott Announces Positive Clinical Results with FIRM-Guided Rotor Ablation for Atrial Fibrillation

Trio of studies presented at Cardiostim conference support technique that allows more individualized treatment of cardiac arrhythmias

Abbott, FIRM-guided rotor ablation, atrial fibrillation, clinical studies, Cardiostim 2016

July 7, 2016 — Abbott recently announced positive results from three clinical studies investigating the benefits associated with focal impulse rotor modulation (FIRM)-guided rotor ablation for atrial fibrillation. The investigator-sponsored studies, which evaluated the use of Abbott’s RhythmView technology, were presented at the Cardiostim-EHRA Europace 2016 conference, June 8-11 in Nice, France.

FIRM-guided therapy enables physicians to identify and locate rotors – unique patient-specific sources that sustain serious heart rhythm disorders, including atrial fibrillation. With the ability to visualize individual rotors, physicians can tailor treatment approaches for each patient.

“The latest data presented at Cardiostim adds to a growing body of clinical evidence in support of the FIRM-guided approach in combination with conventional ablation, with the goals of optimizing treatment planning for atrial fibrillation and improving long-term results for our patients,” said Prof. Stefan Spitzer of the Praxisklinik Herz und Gefäße in Dresden, Germany, who authored one of the data presentations at the conference. “I look forward to additional analyses that further investigate this important therapy option.”

The studies presented at Cardiostim investigated the benefits associated with FIRM-guided rotor ablation when combined with the traditional procedure for atrial fibrillation. Key findings include:

  • Spitzer presented results from 58 patients finding 80.8 percent of patients free from atrial fibrillation at 12 months post-treatment with FIRM-guided ablation for redo cases of persistent atrial fibrillation, with 83 percent of patients having long-standing persistent atrial fibrillation;
  • Tamas Szili-Torok, M.D., Rotterdam, Netherlands, presented the first results from the European-Focal Impulse and Rotor Modulation Registry (E-FIRM) of 138 patients showing 78 percent and 72 percent of patients in sinus rhythm following treatment with the FIRM-guided ablation at six and 12 months, respectively; and
  • Haroon Rashid, M.D., Falls Church, Va., shared data examining the relationship between stable rotors and obstructive sleep apnea in 47 patients, showing 78.6 percent of patients in sinus rhythm after FIRM-guided ablation, despite the presence of obstructive sleep apnea.

During a FIRM-guided rotor ablation procedure for atrial fibrillation, physicians use Abbott’s proprietary technology to identify and visualize rotors, important sustaining mechanisms of cardiac arrhythmias. Because arrhythmias develop as a result of both electrical and anatomic abnormalities, every patient needs to be individually diagnosed and treated. The system offers a patient-specific solution that enables physicians, for the very first time, to identify and ablate the unique sources that sustain serious heart rhythm disorders.

Read about first reports on the FIRM rotor mapping technique at HRS.

 

For more information: www.abbott.com

Related Content

ICDs, implantable cardioverter defibrillators, survival rate, elderly patients, JACC study
News | Implantable Cardioverter Defibrillators (ICD)| January 17, 2017
Of patients over age 65 who received an implantable cardioverter-defibrillator (ICD) after surviving sudden cardiac...
University of Utah, Frank Sachse, heart failure, LVAD implantation, left ventricular assist device, biomarker, t-system

Two patients may seem equally sick based upon clinical measures, but differences in their heart physiology could predict who has the potential to recover from heart failure. A study carried out by scientists at the University of Utah finds that patients whose hearts have flattened t-tubules have a decreased chance of showing signs of recovery after implanting a mechanical heart pump. Ordinarily, t-tubules in the heart are long, thin, and rounded. Image courtesy of Frank Sachse.

News | Cardiac Diagnostics| January 17, 2017
Investigators at the University of Utah have identified distinct differences in the hearts of advanced heart failure...
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
St. Jude Medical, Amplatzer Amulet LAA Occluder, observational study, TCT 2016
News | Left Atrial Appendage (LAA) Occluders| November 03, 2016
St. Jude Medical Inc. presented favorable results from the largest observational study to date of the company’s...
Medtronic, CoreValve Evolut R TAVR system, U.S. IDE Study, TCT 2016
News | Heart Valve Technology| November 03, 2016
Medtronic plc unveiled new clinical data showing that patients treated with the self-expanding CoreValve Evolut R...
open-heart surgery, PCI, percutaneous coronary intervention, NOBLE trial, left main coronary artery disease, LMCAD, TCT 2016
News | Cardiovascular Surgery| November 03, 2016
Coronary artery bypass (CABG) surgery is the standard treatment for revascularization in patients with left main...
News | Drug-Eluting Balloons| November 03, 2016
The Spectranetics Corp. announced that it has submitted to the U.S. Food & Drug Administration (FDA) its Pre-Market...
Medtronic, Resolute Integrity DES, drug-eluting stent, BIO-RESORT study, TCT 2016
News | Stents Drug Eluting| November 02, 2016
Investigators recently unveiled clinical data from the independent BIO-RESORT study, representing the first all-comers...
Medtronic, Harmony TPV, transcatheter pulmonary valve, clinical study results, TCT 2016
News | Heart Valve Technology| November 02, 2016
Medtronic plc recently announced new clinical data for the Harmony Transcatheter Pulmonary Valve (TPV) from its early...
Medtronic, Drug-Filled Stent, DFS, RevElution trial, first clinical data, TCT 2016, Stephen Worthley
News | Stents Drug Eluting| November 01, 2016
November 1, 2016 — Medtronic plc unveiled the first clinical outcomes of its novel...
Overlay Init